bioMerieux S.A. (0RUG)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 88.08 |
|---|---|
| 52-week range | 65.90 – 116.10 |
| Return, 1 month / 3 months | +20.5% / +25.6% |
| Return, 1 year / 3 years | −20.9% / +5.0% |
| Trend | Uptrend |
| RSI (14) | 74 |
| Volatility (1 year) | 30.0% |
| Worst drawdown (1 year) | -41.2% |
| Average daily value traded | 5.12M EUR |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
bioMerieux is a French diagnostics company that develops and makes tests and laboratory systems used to detect infectious diseases and other medical conditions. Its products include automated instruments and reagent tests for clinical microbiology, immunodiagnostics and molecular biology, sold to hospitals, laboratories and healthcare providers in many countries. The company is based in France and serves medical and industrial customers who need reliable results for patient care and product safety.
bioMerieux S.A. trades under the code 0RUG on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
bioMerieux S.A. (0RUG) trades on the London Exchange in UK. It last closed at EUR 88.08 on 22 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 2,082 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 20.9% and over the last three months it rose 25.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 48 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 8.5% | ||
| From 52-week high | -23.6% | ||
| Momentum | 52 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 25.6% | ||
| 6-month return | 0.5% | ||
| 12-month return, skipping the last month | -34.4% | ||
| Stability (higher is calmer) | 46 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 30.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.2% | ||
| Liquidity | 68 · Fair | Moderate trading activity. | |
| Average daily value traded | 5.12M EUR | ||
| Zero-volume days | 3.3% | ||
| Income | 29 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.5% |
|---|---|
| 1 month | +20.5% |
| 3 months | +25.6% |
| 6 months | +0.5% |
| 1 year | −20.9% |
| 3 years | +5.0% |
| 5 years | −11.8% |
Signals
| 50-day / 200-day average | 77.13 / 81.18 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.64 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jun 2026 | EUR 0.9800 |
| 9 Jun 2025 | EUR 0.9000 |
| 7 Jun 2024 | EUR 0.8500 |
| 6 Jun 2023 | EUR 0.8500 |
| 6 Jun 2022 | EUR 0.8500 |
| 4 Jun 2021 | EUR 0.6200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.